who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

Abbott Laboratories (ABT) earnings date & Q3 2026 results

US GAAP · quarter ended 09/30/2026 · released Oct 21

Net Earnings

$920M

down 44.0% y/y

Net Sales

$13,013M

up 14.5% y/y

Operating Earnings

$1,358M

down 34.0% y/y

Next report

~ Jan 21

not announced yet

The quarter in brief

Abbott's Q3 2026 net sales rose 14.5% to $13,013 million, but GAAP net earnings fell 44.1% to $920 million. Diluted EPS dropped from $0.94 to $0.53.

Key growth driver: Revenue growth of +14% y/y — the report gives no segment split, so the driver is the whole business. · by the Q3 2026 report

All figures in $M.

Sankey diagram of ABT (Abbott Laboratories) earnings report for Q3 2026: revenue, costs and profitNet Sales$13,013 · +14.5%Cost of productssold, excludingamortizationexpense$5,628 · +10.9%Amortization ofintangible assets$841 · +100%Research anddevelopment$920 · +20.1%Selling, general,andadministrative$4,266 · +39.8%OperatingEarnings$1,358 · −34.0%10.4% marginInterest expense,net$297 · +575%Net foreignexchange (gain)loss$6 · −64.7%Other (income)expense, net$164 · +9.3%Earnings beforetaxes$1,231 · −43.5%Taxes on Earnings$311 · −42.0%25.3% effective rateNet Earnings$920 · −44.0%$0.53/sh · 7.1% margin
Sankey diagram of ABT (Abbott Laboratories) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Net Sales$13,013 · +14.5%
Cost of products sold, excluding amortization expense$5,628 · +10.9%
Amortization of intangible assets$841 · +100%
Research and development$920 · +20.1%
Selling, general, and administrative$4,266 · +39.8%
Operating Earnings$1,358 · −34.0% · 10.4% margin
Interest expense, net$297 · +575%
Net foreign exchange (gain) loss$6 · −64.7%
Other (income) expense, net$164 · +9.3%
Earnings before taxes$1,231 · −43.5%
Taxes on Earnings$311 · −42.0% · 25.3% effective rate
Net Earnings$920 · −44.0% · $0.53/sh · 7.1% margin

Verdict: Abbott's Q3 2026 net sales rose 14.5% to $13,013 million, but GAAP net earnings fell 44.1% to $920 million. Diluted EPS dropped from $0.94 to $0.53.

Abbott narrowed its full-year 2026 adjusted diluted EPS guidance to $5.50–$5.55, keeping the midpoint, and expects comparable sales growth of about 6.0%. Q4 2026 adjusted diluted EPS guidance is $1.62–$1.67. The board declared a quarterly dividend of $0.63 per share, the 411th consecutive one.

Source and notation

Source: Abbott Laboratories press release, 8-K EX-99.1 of 10/21/2026 (SEC EDGAR).

Open as an image: Abbott Laboratories (ABT), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Abbott Laboratories (ABT) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/abt. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/abt"><img src="https://whoreportstoday.com/t/abt/img/abbott-laboratories-abt-earnings-sankey.png" alt="Abbott Laboratories (ABT) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/abt">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/abt/img/abbott-laboratories-abt-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/abt">Abbott Laboratories (ABT) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. · Text: Wikipedia, CC BY-SA 4.0, abridged

The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

Heads-up

Company reports

Q3 2026latest breakdownAbbott's Q3 2026 net sales rose 14.5% to $13,013 million, but GAAP net earnings fell 44.1% to $920 million. Diluted EPS…
Q2 2026Reported sales jumped 13% on the Exact Sciences acquisition and a comparable 4.8% organic gain, but GAAP net income fell…

Company guidance

PeriodCompany guidanceA year agoImplied growth
Q4 2026EPS (non-GAAP) $1.62–1.67revenue $11.46BEPS (GAAP) $1.01—
FY2026EPS (non-GAAP) $5.50–5.55 (reaffirmed)revenue $44.3BEPS (GAAP) $3.72—
How we calculate

EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

Guidance comes from the company's earnings release (Form 8-K filed Oct 21, 2026); every figure is checked against the release text.

The company's release on SEC EDGAR (8-K exhibit) ↗

ABT earnings history: past report dates

Oct 21, 2026 Wed7:36 ambefore market openSep 30, 2026$13.0B+14% y/y$0.53−44% y/y
Jul 16, 2026 Thu7:36 ambefore market openJun 30, 2026$12.6B+13% y/y$0.53−48% y/y
Apr 16, 2026 Thu7:36 ambefore market openMar 31, 2026$11.2B+8% y/y$0.61−20% y/y
Jan 22, 2026 Thu7:35 ambefore market openDec 31, 2025≈$11.5B+4% y/y≈$1.01−81% y/y
Oct 15, 2025 Wed7:33 ambefore market openSep 30, 2025$11.4B+7% y/y$0.94+0% y/y
Jul 17, 2025 Thu7:34 ambefore market openJun 30, 2025$11.1B+7% y/y$1.01+36% y/y
Apr 16, 2025 Wed7:36 ambefore market openMar 31, 2025$10.4B+4% y/y$0.76+9% y/y
Jan 22, 2025 Wed7:13 ambefore market openDec 31, 2024≈$11.0B+7% y/y≈$5.26+478% y/y
Oct 16, 2024 Wed7:37 ambefore market openSep 30, 2024$10.6B+5% y/y$0.94+15% y/y
Jul 18, 2024 Thu7:37 ambefore market openJun 30, 2024$10.4B+4% y/y$0.74−5% y/y
Apr 17, 2024 Wed7:36 ambefore market openMar 31, 2024$10.0B+2% y/y$0.70−7% y/y
Jan 24, 2024 Wed7:36 ambefore market openDec 31, 2023≈$10.2B+1% y/y≈$0.91+54% y/y
Oct 18, 2023 Wed7:37 ambefore market openSep 30, 2023$10.1B−3% y/y$0.82+1% y/y
Jul 20, 2023 Thu8:29 ambefore market openJun 30, 2023$10.0B−11% y/y$0.78−32% y/y
Apr 19, 2023 Wed7:25 ambefore market openMar 31, 2023$9.7B−18% y/y$0.75−45% y/y
Jan 25, 2023 Wed7:38 ambefore market openDec 31, 2022≈$10.1B−12% y/y≈$0.59−47% y/y
Show all 16 reports since 2023Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Abbott Laboratories: 15-year financials

202544,3288,0536,5247,3954,116
202441,9506,82513,4026,3513,836
202340,1096,4785,7235,0593,556
202243,6538,3626,9337,8043,309
202143,0758,4257,0718,6483,202
202034,6085,3574,4955,7242,560
201931,9044,5323,6874,4982,270
201830,5783,6502,3684,9061,974
201727,3901,5644774,4351,849
201620,8533,0261,4002,0821,539
201520,4052,8674,4231,8561,443
201420,2472,5992,2842,5981,342
201319,6572,1332,5762,179882
201219,0501,3605,9637,5193,183
201121,4071,6294,7287,4792,938

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Abbott Laboratories: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
202586,71352,13012,9298,52225,99616,496
202481,41447,66414,1257,61623,65614,157
202373,21438,60314,6796,89622,67013,841
202274,43836,68616,7739,88225,22415,489
202175,19635,80218,0509,79924,23913,105
202072,54832,78418,7476,83820,44111,907
201967,88731,08818,1393,86015,66710,863
201867,17330,52419,5663,84414,6329,012
201776,25030,89727,9249,40720,1478,912
201652,66620,53822,00618,62026,7766,660
201541,24721,2119,0015,00114,1559,186
201441,20721,5267,8304,06313,55610,467
201342,93725,1716,5613,47519,2479,507
201267,23526,72120,47610,80231,32313,280
201160,27724,44015,4156,81323,76915,480

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

9 months ended 2026-09-30 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated5,5406,251−711
· incl. D&A (non-cash add-back)depreciation & amortization1,1981,064
· incl. stock-based comp (non-cash)share-based compensation622551
Capexpurchases of property & equipment−1,409−1,482+73
Free cash flow ≈operating cash flow − capex4,1314,769−638
Investing activities, netcapex, acquisitions, securities−21,382−1,509−19,873
Financing activities, netdebt, buybacks, dividends11,390−4,912+16,302
· incl. buybacksrepurchases of common stock−1,236−591−645
· incl. dividends paid−3,294−3,086−208
Net change in cash−4,470−105−4,365
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Sep 30, 2026: $51.0B (47% of total assets). Compare with other S&P 500 companies →

Corporate governance

2/2good

  • Feb 2026Per the 2025 10-K, Abbott has a single share class (Common Shares); declared dividend of $2.40 per share vs. $2.24 a year earlier (+7.1%). sec.gov ↗
  • Dec 2025Diluted shares fell 2.1% over 2020–2025; SBC of $0.66B = 1.5% of $44.3B revenue. data.sec.gov ↗
2 more facts and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Apr 2026An 8-K disclosed a settlement of the shareholder derivative suit over infant formula (In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation) — with no payout borne by shareholders. sec.gov ↗
  • Feb 2026Legal Proceedings in the 2025 10-K lists no settled suits for misleading investors and no SEC cases; the DOJ is running a product investigation into infant formula. sec.gov ↗

Scoring: 2.0, no deductions: single share class, share count −2% over 5 years, SBC 1.5% of revenue, dividend raised every year; investor suit over infant formula dismissed, derivative suit settled in the company's favor

Share classes
Single class: Common Shares (2025 10-K cover); cumulative voting in board elections.
Dilution
Diluted shares −2.1% over 2020–2025 (XBRL), SBC 1.5% of revenue.
Disclosure
Full US GAAP reporting: 10-K and 10-Q filed on EDGAR on time.
Dividends
Dividend raised every year: $2.08 → $2.24 → $2.40 over 2023–2025; quarterly payout raised to $0.63 from 02/2026 (10-K).
Lawsuits & regulators
The investor class action over the Sturgis plant was not settled with a payout (dismissed, per media reports) — no deduction; the derivative suit was settled (2026) with a $40M capex commitment and reforms, with the company as beneficiary; the DOJ formula probe is product-related, no deduction.
Related parties
Committee approval policy for related-party transactions; no material transactions disclosed in the 2026 proxy.

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap

Abbott Laboratories (ABT) earnings: FAQ

When is ABT's next earnings date?

We have not yet seen an announcement of the date from Abbott Laboratories (ABT). Based on last year's report on Jan 22, 2026, the next report is expected around Jan 21, 2027.

What time does ABT report earnings?

Abbott Laboratories usually reports before market open: its latest results release was filed with the SEC at 7:36 am ET on Oct 21, 2026.

When did ABT last report earnings?

Abbott Laboratories reported Q3 2026 results on Oct 21, 2026.

What has Abbott Laboratories guided for Q4 2026?

Company guidance for Q4 2026: EPS (non-GAAP) $1.62–1.67. A year ago (Q4 2025): revenue $11.46B, EPS (GAAP) $1.01. Company guidance for FY2026: EPS (non-GAAP) $5.50–5.55 (reaffirmed). A year ago (FY2025): revenue $44.3B, EPS (GAAP) $3.72. Source: the company's earnings release (Form 8-K filed Oct 21, 2026).

Where can I find Abbott Laboratories's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to ABT's filings; this page breaks the latest report down in a Sankey chart.

What was ABT's net income in Q3 2026?

Abbott Laboratories reported net income of $920M for Q3 2026 (−44.0% year over year), under US GAAP.

Does Abbott Laboratories pay dividends?

Yes. In 2025, Abbott Laboratories paid $4,116M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.

How has Abbott Laboratories's revenue changed since 2011?

Per its 10-K filings, revenue grew 2.1x: $21,407M in 2011 and $44,328M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: ALGN · Q3 2026 · AMGN · Q3 2026 · BAX · Q3 2026 · BDX · Q4 FY2026 · BIIB · Q3 2026 · BMY · Q3 2026 · BSX · Q3 2026 · CAH · Q1 FY2027 · CI · Q3 2026 · CNC · Q3 2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy